Company news

Gilead Sciences, Inc. news in 2022

Gilead Sciences, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

December 26, 2022

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

December 8, 2022

European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

November 28, 2022

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

November 27, 2022

Gilead's Path to Equitable Global COVID-19 Treatment Access

November 1, 2022

Gilead Sciences Announces Third Quarter 2022 Financial Results

October 26, 2022

Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers

October 19, 2022

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

October 16, 2022

Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022

October 12, 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer

October 10, 2022

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

October 2, 2022

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

September 21, 2022

Gilead Sciences Completes Acquisition of MiroBio

September 19, 2022

Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

September 15, 2022

Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity

September 12, 2022

Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

September 5, 2022

Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

August 21, 2022

Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

August 16, 2022

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®

August 14, 2022

Gilead Sciences to Acquire MiroBio

August 3, 2022

Gilead Sciences Announces Second Quarter 2022 Financial Results

August 1, 2022

Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

July 21, 2022

Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity

July 19, 2022

Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)

July 18, 2022

Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

July 11, 2022

Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

June 27, 2022

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

June 26, 2022

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

June 1, 2022

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

May 1, 2022

Gilead Sciences Announces First Quarter 2022 Financial Results

April 27, 2022

Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

April 24, 2022

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland

April 18, 2022

Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022

April 13, 2022

Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere

March 27, 2022

Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer

March 6, 2022

Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues

February 28, 2022

New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor

February 15, 2022

Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

February 10, 2022

Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend

January 31, 2022

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

January 24, 2022

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

January 20, 2022

Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022

January 17, 2022

Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer

January 9, 2022

Calls in 2022

Decks in 2022